NHS in England to widely roll out Tisagenlecleucel (Kymriah) blood cancer treatment, following Nice's approval.

Life-saving blood cancer treatment, Tisagenlecleucel (Kymriah), set to be widely rolled out on NHS in England following Nice's approval. A personalised Car-T therapy, it reprograms patients' immune system cells to target cancer. Currently available for B-cell acute lymphoblastic leukaemia patients via Cancer Drugs Fund since 2018, Nice has recommended its routine rollout for eligible patients aged 25 and under.

April 11, 2024
3 Articles